Table 2.

Summary of PX-loaded Lipid-based NPs. (*EE=Entrapment Efficiency).

Platform	Composition	% EE*	Particle Size (nm)	Status	Ref.
Liposomes	phosphatidylcholine, cholesterol, cardiolipin	>90	~150	in-vitro	[116]
	HSPC, cholesterol, PEG-DSPE	—	~100	in-vivo	[117]
	phosphatidylglycerol, phosphatidylcholine	—	200, 900	in-vivo	[118]
Solid Lipid Nanoparticles	tripalmitin, Epikuron 20, butanol, Na-taurocholate, cholesteryl hemisuccinate	—	160	in-vitro	[121]
	stearic acid, lecithin, Brij 78 (or pluronic F68 and DSPE-PEG)	58-75	100-220	in-vivo	[122]
	trimyristin, EPC, PEG2000-PE	72-89	200-250	in-vivo	[123, 124]
	glyceryl palmitostearate (or glyceryl monostearate), poloxamer 407	55-90	~200	in-vitro	[127, 128]
	Lipoid S 100, sucrose fatty acid esters	89-92	150-190	in-vitro	[129]
	stearylamine, soya lecithin, poloxamer 188	75	70-130	in-vivo	[125]
	monostearin, stearic acid, glycerol tristearate, ATO 888	36-76	160-260	in-vitro	[126]
	emulsifying wax, Brij 78	~50	<100	in-vivo	[130, 131]
	glyceryl tridodecanoate, Brij 78	>85	170	in-vitro	[132, 133]
Lipid Nanocapsules	Labrafac®, Lipoïd® S75-3, Solutol® HS15	—	~50	in-vivo	[134-136]
	Captex® 8000, Lipoïd® S75-3, Solutol® HS15	93	~50	in-vivo	[137-140]
	Miglyol 812, Brij 78, TPGS	85-97	~200	in-vivo	[132, 133]
	PLGA, lecithin, DSPE-PEG2000, DSPC, RGD (targeting)	82	68	in-vivo	[142, 143]
	Lipiodol, PEO-PPO-PEO, functionalized PEG, folic acid (targeting)	46	110	in-vivo	[144]
	lecithin, Dynasan 118, Miglyol 812, folate-PEG-PE, Span 60 (or PEG PE)	98	207	in-vivo	[145]
Micro- and Nano- Emulsions	vitamin E, TPGS, poloxamer 407	—	100	phase III / discontinued	[154]
	oil blend, EPC, Tween 80, glycerol	>95	150	in-vivo	[156]
	lecithin, butanol, myvacet (or capmul, myvacet)	—	~110	in-vivo	[157, 158]
	pine nut oil, egg lecithin, stearylamine, deoxycholic acid	—	90-120	in-vivo	[159]
	egg lecithin, flaxseed oil, DSPE-PEG2000	97-100	130-150	in-vitro	[160]

^*(EE=Entrapment Efficiency).